The pharmacokinetics of ketoconazole in severely immunocompromised patients

Forty patients severely immunocompromised because of the nature of their underlying disease (marrow aplasia, acute leukaemia or solid tumour) and/or the treatment they were receiving, received ketoconazole 400 mg daily. All patients also received gut decontamination with non-absorbable antibiotics,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 1982-12, Vol.10 (6), p.489-496
Main Authors: Hann, I. M., Prentice, H. G., Keaney, M., Corringham, R., Blacklock, H. A., Fox, J., Gascoigne, E., Van Custem, J.
Format: Article
Language:English
Subjects:
Adult
Antifungal Agents - metabolism
Bone Marrow Transplantation
Female
Humans
Imidazoles - metabolism
Immune Tolerance
Ketoconazole
Kinetics
Leukemia - immunology
Leukemia - metabolism
Male
Piperazines - metabolism
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c324t-37234e0fe312d08efeea5d02d9fe6a2b6ca6a9e0a534e5973a5c24d4ab890f623
cites
container_end_page 496
container_issue 6
container_start_page 489
container_title Journal of antimicrobial chemotherapy
container_volume 10
creator Hann, I. M.
Prentice, H. G.
Keaney, M.
Corringham, R.
Blacklock, H. A.
Fox, J.
Gascoigne, E.
Van Custem, J.
description Forty patients severely immunocompromised because of the nature of their underlying disease (marrow aplasia, acute leukaemia or solid tumour) and/or the treatment they were receiving, received ketoconazole 400 mg daily. All patients also received gut decontamination with non-absorbable antibiotics, skin antisepsis, sterile food and oral co-trimoxazole. Mean (±S.D.) peak serum ketoconazole levels of 5·14±1·4 mg/l occurred 3 h after drug intake. In patients not receiving an allogeneic bone marrow transplant (BMT), the mean serum level at 2 h post-dose remained in the range of 3 to 5 mg/l during prolonged therapy. In contrast, serum ketoconazole levels in allogeneic BMT patients declined during continued treatment. In addition, the incidence of fungal infections was significantly higher in allogeneic-BMT patients than in the other group (P
doi_str_mv 10.1093/jac/10.6.489
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80295148</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80295148</sourcerecordid><originalsourceid>FETCH-LOGICAL-c324t-37234e0fe312d08efeea5d02d9fe6a2b6ca6a9e0a534e5973a5c24d4ab890f623</originalsourceid><addsrcrecordid>eNo9kE1Lw0AURQdRaq3u3ApZuTLtfCezlKJWWhGhQnEzTCcvNG2SqZlErL_eKS1dvQvncHlchG4JHhKs2Ght7ChkOeSpOkN9wiWOKVbkHPUxwyJOuGCX6Mr7NcZYCpn2UE9SlZKE9NF0voJouzJNZazbFDW0hfWRy6MNtM662vy5EqKijjz8QAPlLiqqqqsDqraNqwoPWbQ1bQF166_RRW5KDzfHO0Cfz0_z8SSevb-8jh9nsWWUtzFLKOOAc2CEZjiFHMCIDNNM5SANXUprpFGAjQiaUAkzwlKecbNMFc4lZQN0f-gNH3x34Fsd_rBQlqYG13mdYqoE4WkQHw6ibZz3DeR62xSVaXaaYL3fToft9lnqsF3Q74693bKC7CQfxwo8PvDCt_B7wqbZaJmwROjJ4ktLtvh4mzIRwj-I-nsH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80295148</pqid></control><display><type>article</type><title>The pharmacokinetics of ketoconazole in severely immunocompromised patients</title><source>Oxford University Press Archive</source><creator>Hann, I. M. ; Prentice, H. G. ; Keaney, M. ; Corringham, R. ; Blacklock, H. A. ; Fox, J. ; Gascoigne, E. ; Van Custem, J.</creator><creatorcontrib>Hann, I. M. ; Prentice, H. G. ; Keaney, M. ; Corringham, R. ; Blacklock, H. A. ; Fox, J. ; Gascoigne, E. ; Van Custem, J.</creatorcontrib><description>Forty patients severely immunocompromised because of the nature of their underlying disease (marrow aplasia, acute leukaemia or solid tumour) and/or the treatment they were receiving, received ketoconazole 400 mg daily. All patients also received gut decontamination with non-absorbable antibiotics, skin antisepsis, sterile food and oral co-trimoxazole. Mean (±S.D.) peak serum ketoconazole levels of 5·14±1·4 mg/l occurred 3 h after drug intake. In patients not receiving an allogeneic bone marrow transplant (BMT), the mean serum level at 2 h post-dose remained in the range of 3 to 5 mg/l during prolonged therapy. In contrast, serum ketoconazole levels in allogeneic BMT patients declined during continued treatment. In addition, the incidence of fungal infections was significantly higher in allogeneic-BMT patients than in the other group (P&lt;0·005).</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/10.6.489</identifier><identifier>PMID: 6298171</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adult ; Antifungal Agents - metabolism ; Bone Marrow Transplantation ; Female ; Humans ; Imidazoles - metabolism ; Immune Tolerance ; Ketoconazole ; Kinetics ; Leukemia - immunology ; Leukemia - metabolism ; Male ; Piperazines - metabolism</subject><ispartof>Journal of antimicrobial chemotherapy, 1982-12, Vol.10 (6), p.489-496</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c324t-37234e0fe312d08efeea5d02d9fe6a2b6ca6a9e0a534e5973a5c24d4ab890f623</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6298171$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hann, I. M.</creatorcontrib><creatorcontrib>Prentice, H. G.</creatorcontrib><creatorcontrib>Keaney, M.</creatorcontrib><creatorcontrib>Corringham, R.</creatorcontrib><creatorcontrib>Blacklock, H. A.</creatorcontrib><creatorcontrib>Fox, J.</creatorcontrib><creatorcontrib>Gascoigne, E.</creatorcontrib><creatorcontrib>Van Custem, J.</creatorcontrib><title>The pharmacokinetics of ketoconazole in severely immunocompromised patients</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Forty patients severely immunocompromised because of the nature of their underlying disease (marrow aplasia, acute leukaemia or solid tumour) and/or the treatment they were receiving, received ketoconazole 400 mg daily. All patients also received gut decontamination with non-absorbable antibiotics, skin antisepsis, sterile food and oral co-trimoxazole. Mean (±S.D.) peak serum ketoconazole levels of 5·14±1·4 mg/l occurred 3 h after drug intake. In patients not receiving an allogeneic bone marrow transplant (BMT), the mean serum level at 2 h post-dose remained in the range of 3 to 5 mg/l during prolonged therapy. In contrast, serum ketoconazole levels in allogeneic BMT patients declined during continued treatment. In addition, the incidence of fungal infections was significantly higher in allogeneic-BMT patients than in the other group (P&lt;0·005).</description><subject>Adult</subject><subject>Antifungal Agents - metabolism</subject><subject>Bone Marrow Transplantation</subject><subject>Female</subject><subject>Humans</subject><subject>Imidazoles - metabolism</subject><subject>Immune Tolerance</subject><subject>Ketoconazole</subject><subject>Kinetics</subject><subject>Leukemia - immunology</subject><subject>Leukemia - metabolism</subject><subject>Male</subject><subject>Piperazines - metabolism</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1982</creationdate><recordtype>article</recordtype><recordid>eNo9kE1Lw0AURQdRaq3u3ApZuTLtfCezlKJWWhGhQnEzTCcvNG2SqZlErL_eKS1dvQvncHlchG4JHhKs2Ght7ChkOeSpOkN9wiWOKVbkHPUxwyJOuGCX6Mr7NcZYCpn2UE9SlZKE9NF0voJouzJNZazbFDW0hfWRy6MNtM662vy5EqKijjz8QAPlLiqqqqsDqraNqwoPWbQ1bQF166_RRW5KDzfHO0Cfz0_z8SSevb-8jh9nsWWUtzFLKOOAc2CEZjiFHMCIDNNM5SANXUprpFGAjQiaUAkzwlKecbNMFc4lZQN0f-gNH3x34Fsd_rBQlqYG13mdYqoE4WkQHw6ibZz3DeR62xSVaXaaYL3fToft9lnqsF3Q74693bKC7CQfxwo8PvDCt_B7wqbZaJmwROjJ4ktLtvh4mzIRwj-I-nsH</recordid><startdate>198212</startdate><enddate>198212</enddate><creator>Hann, I. M.</creator><creator>Prentice, H. G.</creator><creator>Keaney, M.</creator><creator>Corringham, R.</creator><creator>Blacklock, H. A.</creator><creator>Fox, J.</creator><creator>Gascoigne, E.</creator><creator>Van Custem, J.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198212</creationdate><title>The pharmacokinetics of ketoconazole in severely immunocompromised patients</title><author>Hann, I. M. ; Prentice, H. G. ; Keaney, M. ; Corringham, R. ; Blacklock, H. A. ; Fox, J. ; Gascoigne, E. ; Van Custem, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c324t-37234e0fe312d08efeea5d02d9fe6a2b6ca6a9e0a534e5973a5c24d4ab890f623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1982</creationdate><topic>Adult</topic><topic>Antifungal Agents - metabolism</topic><topic>Bone Marrow Transplantation</topic><topic>Female</topic><topic>Humans</topic><topic>Imidazoles - metabolism</topic><topic>Immune Tolerance</topic><topic>Ketoconazole</topic><topic>Kinetics</topic><topic>Leukemia - immunology</topic><topic>Leukemia - metabolism</topic><topic>Male</topic><topic>Piperazines - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hann, I. M.</creatorcontrib><creatorcontrib>Prentice, H. G.</creatorcontrib><creatorcontrib>Keaney, M.</creatorcontrib><creatorcontrib>Corringham, R.</creatorcontrib><creatorcontrib>Blacklock, H. A.</creatorcontrib><creatorcontrib>Fox, J.</creatorcontrib><creatorcontrib>Gascoigne, E.</creatorcontrib><creatorcontrib>Van Custem, J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hann, I. M.</au><au>Prentice, H. G.</au><au>Keaney, M.</au><au>Corringham, R.</au><au>Blacklock, H. A.</au><au>Fox, J.</au><au>Gascoigne, E.</au><au>Van Custem, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The pharmacokinetics of ketoconazole in severely immunocompromised patients</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>1982-12</date><risdate>1982</risdate><volume>10</volume><issue>6</issue><spage>489</spage><epage>496</epage><pages>489-496</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><abstract>Forty patients severely immunocompromised because of the nature of their underlying disease (marrow aplasia, acute leukaemia or solid tumour) and/or the treatment they were receiving, received ketoconazole 400 mg daily. All patients also received gut decontamination with non-absorbable antibiotics, skin antisepsis, sterile food and oral co-trimoxazole. Mean (±S.D.) peak serum ketoconazole levels of 5·14±1·4 mg/l occurred 3 h after drug intake. In patients not receiving an allogeneic bone marrow transplant (BMT), the mean serum level at 2 h post-dose remained in the range of 3 to 5 mg/l during prolonged therapy. In contrast, serum ketoconazole levels in allogeneic BMT patients declined during continued treatment. In addition, the incidence of fungal infections was significantly higher in allogeneic-BMT patients than in the other group (P&lt;0·005).</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>6298171</pmid><doi>10.1093/jac/10.6.489</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0305-7453
ispartof Journal of antimicrobial chemotherapy, 1982-12, Vol.10 (6), p.489-496
issn 0305-7453
1460-2091
language eng
recordid cdi_proquest_miscellaneous_80295148
source Oxford University Press Archive
subjects Adult
Antifungal Agents - metabolism
Bone Marrow Transplantation
Female
Humans
Imidazoles - metabolism
Immune Tolerance
Ketoconazole
Kinetics
Leukemia - immunology
Leukemia - metabolism
Male
Piperazines - metabolism
title The pharmacokinetics of ketoconazole in severely immunocompromised patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A46%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20pharmacokinetics%20of%20ketoconazole%20in%20severely%20immunocompromised%20patients&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Hann,%20I.%20M.&rft.date=1982-12&rft.volume=10&rft.issue=6&rft.spage=489&rft.epage=496&rft.pages=489-496&rft.issn=0305-7453&rft.eissn=1460-2091&rft_id=info:doi/10.1093/jac/10.6.489&rft_dat=%3Cproquest_cross%3E80295148%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c324t-37234e0fe312d08efeea5d02d9fe6a2b6ca6a9e0a534e5973a5c24d4ab890f623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=80295148&rft_id=info:pmid/6298171&rfr_iscdi=true